Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
SQLLW SEQLL INC C/WTS 31/08/2026 (TO PUR COM)
0.130-0.035-21.21%
Trading Session
02/08 11:53 ET
High
0.200
Open
0.150
Turnover
7.81K
Low
0.130
Pre Close
0.165
Volume
47.64K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
SEQLL INC. GRANTED SECOND 180-DAY EXTENSION BY NASDAQ REGARDING MINIMUM BID REQUIREMENTS
BILLERICA, MA, Dec. 22, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (NASDAQ:SQL) ("SeqLL" or the "Company"), a technology company providing life sciences instrumentation and research services, announced that on December 20,
UPDATE -- SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology
BILLERICA, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today an
SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature Biotechnology
BILLERICA, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today an
SeqLL to Present at the H.C. Wainwright 24th Annual Global Conference
BILLERICA, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services fo
SeqLL Inc. Receives Nasdaq Notification Regarding Minimum Bid Requirements
BILLERICA, Mass., June 24, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (NASDAQ: SQL and SQLLW) ("SeqLL" or the "Company"), a technology company providing life sciences instrumentation and research services
SeqLL’s Single-Molecule Nucleosome Imaging Method Published in Peer Reviewed Cell Reports Journal
BILLERICA, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in
SeqLL Provides First Quarter 2022 Financial Results and a Corporate Update
BILLERICA, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in c
SeqLL Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
BILLERICA, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services in
SeqLL to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest
BILLERICA, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services fo
SeqLL Announces Formation of Scientific Advisory Board
BILLERICA, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. ("SeqLL" or the "Company") (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services fo
Company Overview
More
SeqLL, Inc. engages in the design, development, and manufacture of genetic analysis technologies. Its services include RNA sequencing and DNA sequencing. The company was founded by William C. St. Laurent and Daniel R. Jones in 2013 and is headquartered in Billercia, MA.
CEO： Mr. Daniel Jones
Market： NASDAQ
Listing Date： 08/27/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet